Alopecia Areata vs. Female Pattern Hair Loss: Telling Them Apart

Why This Comparison Matters

Two of the most distressing hair-loss conditions affecting women — alopecia areata (AA) and female pattern hair loss (FPHL) — are frequently confused, both by patients and by non-specialist clinicians. They can look superficially similar in photographs and both cause real, significant psychological impact. But their underlying mechanisms are completely different, their clinical courses diverge, and critically, treatments that work for one do not work for the other.

Getting the diagnosis right is the necessary starting point. This page lays out the key differences across every relevant dimension.

The Core Distinction at a Glance

Mechanism: Fundamentally Different Diseases

Alopecia Areata: An Autoimmune Follicle Attack

In alopecia areata, the hair follicle's normal state of immune privilege — which protects it from the immune system — collapses. CD8+ T cells infiltrate the follicle and release interferon-gamma (IFN-γ), which signals through the JAK-STAT pathway (JAK1/JAK2) to arrest hair growth prematurely. The follicle is not destroyed; it is suspended in a state of suppressed activity. This reversibility explains why even long-standing extensive hair loss can recover.

Genetic susceptibility loci (≥16 confirmed, including HLA class I/II alleles) create the predisposition, and environmental triggers (viral infection, stress, hormonal shifts) precipitate episodes.

Female Pattern Hair Loss: Follicle Miniaturization

FPHL is caused by progressive miniaturization of genetically susceptible hair follicles. Terminal hairs — which are thick, long, and pigmented — are progressively converted to vellus-like hairs that are shorter, finer, and less pigmented. Eventually, affected follicles may cycle through so rapidly that the hair barely reaches the surface before being shed.

The role of androgens is complex and incompletely understood. Unlike male androgenetic alopecia, where dihydrotestosterone (DHT) is a well-established driver, most women with FPHL have normal serum androgen levels — which is why the preferred term is "female pattern hair loss" rather than "female androgenetic alopecia." Sensitivity of hair follicles to normal androgen levels, rather than androgen excess per se, appears to be the operative mechanism. Post-menopausal estrogen decline is associated with worsening, suggesting estrogens are protective. FPHL is polygenic with strong hereditary components.

Clinical Presentation: How They Look

Alopecia Areata

• One or more smooth, sharply defined round or oval patches of complete hair loss
• Affected skin appears normal — no redness, no scaling, no scarring
• At active patch margins: exclamation mark hairs — short, broken strands that taper toward the scalp (thinner proximally than distally). These are pathognomonic: they are not seen in any other hair loss condition.
• Dermoscopy reveals: yellow dots (follicles in telogen), black dots (broken hair shafts), dystrophic hairs, and exclamation mark hairs — all markers of disease activity
• Can affect eyebrows, eyelashes, beard, and body hair as well as scalp
• Nail changes in 10–40% of patients: pitting, trachyonychia, Beau's lines
• The patient often notices the patch suddenly, sometimes discovered by someone else

Female Pattern Hair Loss

• Diffuse thinning across the crown and parietal scalp — the central part gradually widens
• The frontal hairline is typically preserved — a key distinguishing feature from male androgenetic alopecia and from AA when extensive
• "Christmas tree pattern": the thinning creates a triangular widening of the part, broadest anteriorly and narrowing toward the crown
• No exclamation mark hairs; no smooth bald patches (unless very advanced)
• Dermoscopy shows: hair shaft diameter variability (>20% of hairs miniaturized is diagnostic), reduced follicular unit density, and perifollicular discoloration
• Gradual progression — many women first notice it when they see photographs or when a hairdresser comments; by the time hair loss is perceptible, up to 50% of hair density may already have been lost
• Ludwig classification grades severity from I (mild widening of part) to III (marked thinning with see-through areas on crown)
• Scalp skin is entirely normal — no pathological signs

The Pitfall: When They Look Similar

Two AA subtypes can convincingly mimic FPHL:

Diffuse alopecia areata: Rather than discrete patches, some patients lose hair in a rapid, widespread pattern across the entire scalp, creating the appearance of general thinning. This is uncommon but easily confused with FPHL.

Sisaipho (ophiasis inversus): A rare AA subtype in which hair loss tracks along the frontal, temporal, and parietal scalp while the occipital region is spared — the inverse of the typical ophiasis band. This pattern closely resembles the distribution of FPHL.

In both cases, dermoscopy distinguishes them: AA will show yellow dots, black dots, and dystrophic hairs; FPHL will show diameter variability and miniaturized units. Scalp biopsy is definitive when dermoscopy is inconclusive.

Diagnosis: How Each Is Confirmed

Alopecia Areata

Clinical diagnosis is usually made by a dermatologist based on the pattern of smooth patches, exclamation mark hairs, and dermoscopy. Pull test at the patch margin (positive if >10% of grasped hairs shed easily) supports active disease. Blood tests assess for associated autoimmune comorbidities: TSH (thyroid), CBC, ferritin. Scalp biopsy is reserved for atypical presentations and shows the characteristic "bee-swarm" perifollicular lymphocytic infiltrate around anagen follicles.

Female Pattern Hair Loss

Diagnosis is clinical, supported by dermoscopy showing ≥20% diameter variability. Ludwig grade is assigned by inspection of the crown with the hair parted. Blood tests rule out secondary causes: TSH, ferritin, full blood count, and in women with signs of androgen excess (acne, hirsutism, irregular periods), hormonal panel (free/total testosterone, DHEAS, sex hormone binding globulin, prolactin) to exclude PCOS or congenital adrenal hyperplasia. Most women with FPHL will have normal hormones. Scalp biopsy is the gold standard for diagnosis in ambiguous cases.

Treatment: Completely Different Approaches

Treating AA With FPHL Treatments — and Vice Versa

Minoxidil does not treat the autoimmune process in AA (it may help stimulate follicle cycling as an adjunct, but it cannot stop the immune attack). Anti-androgens and finasteride have no role in AA. Conversely, JAK inhibitors, which work by blocking the cytokine cascade in AA's autoimmune mechanism, are not approved for FPHL and have no established role in its treatment.

Prognosis: Different Long-Term Trajectories

Alopecia areata has an unpredictable, relapsing course. Mild patchy disease may remit spontaneously — approximately 34–50% of patients with limited disease recover within one year, though recurrence is the norm. Severe subtypes (totalis/universalis) have much lower spontaneous remission rates (under 10–18%). Follicles are never permanently destroyed.

FPHL is progressive without treatment — it does not spontaneously remit. Without minoxidil or anti-androgen therapy, most women experience worsening thinning over decades. Treatment slows or halts progression and may produce some regrowth; it does not reverse established miniaturization. Consistent, long-term treatment is required to maintain any benefit.

When to See a Dermatologist

Self-diagnosis of hair loss type is unreliable. Both conditions share the feature of psychologically distressing hair loss, and diffuse AA or sisaipho can be indistinguishable from FPHL without dermoscopy. A board-certified dermatologist can confirm the diagnosis and distinguish AA from FPHL, telogen effluvium, tinea capitis, frontal fibrosing alopecia, and other conditions. This distinction is not academic — the wrong treatment will waste months and potentially allow the condition to progress untreated.

See a dermatologist if:

• Hair loss appears sudden or patchy
• You are unsure of the cause of your hair loss
• Hair loss includes eyebrows or eyelashes
• OTC treatments (minoxidil for FPHL) have been used consistently for six months without benefit
• Hair loss is significantly affecting your quality of life or mental health